These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37477771)

  • 1. Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.
    Di Marco T; Scammell TE; Meinel M; Seboek Kinter D; Datta AN; Zammit G; Dauvilliers Y
    CNS Drugs; 2023 Jul; 37(7):639-653. PubMed ID: 37477771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
    Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
    Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
    Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
    CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.
    Dauvilliers Y; Zammit G; Fietze I; Mayleben D; Seboek Kinter D; Pain S; Hedner J
    Ann Neurol; 2020 Mar; 87(3):347-356. PubMed ID: 31953863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daridorexant in Insomnia Disorder: A Profile of Its Use.
    Nie T; Blair HA
    CNS Drugs; 2023 Mar; 37(3):267-274. PubMed ID: 36754930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Chalet FX; Luyet PP; Rabasa C; Vaillant C; Saskin P; Ahuja A; Citrome L
    Postgrad Med; 2024 May; 136(4):396-405. PubMed ID: 38814132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study.
    Dorsey CM; Lee KA; Scharf MB
    Clin Ther; 2004 Oct; 26(10):1578-86. PubMed ID: 15598474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
    Roth T; Krystal A; Steinberg FJ; Singh NN; Moline M
    Sleep; 2013 Feb; 36(2):189-96. PubMed ID: 23372266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T; Soubrane C; Titeux L; Walsh JK;
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia.
    Najib J; Toderika Y; Dima L
    Am J Ther; 2023 Jul-Aug 01; 30(4):e360-e368. PubMed ID: 37449930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis.
    Dutta S; Singhal S; Shah R; Charan J; Dhingra S; Haque M
    Expert Opin Drug Saf; 2023; 22(12):1237-1251. PubMed ID: 37526060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
    Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
    Ufer M; Kelsh D; Schoedel KA; Dingemanse J
    Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder - A pooled post hoc analysis of two randomized Phase 3 clinical studies.
    Di Marco T; Djonlagic I; Dauvilliers Y; Sadeghi K; Little D; Datta AN; Hubbard J; Hajak G; Krystal A; Olivieri A; Parrino L; Puryear CB; Zammit G; Donoghue J; Scammell TE
    Sleep; 2024 Apr; ():. PubMed ID: 38644625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder.
    Zammit G; Dauvilliers Y; Pain S; Sebök Kinter D; Mansour Y; Kunz D
    Neurology; 2020 May; 94(21):e2222-e2232. PubMed ID: 32341187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daridorexant for the treatment of insomnia disorder: findings and implications.
    Dos Santos JBR; da Silva MRR
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.